Clover Biopharmaceuticals | Other Diseases

Impact on Populations

Chemotherapy-induced thrombocytopenia is a serious, chemotherapy-associated complication characterized by a low count of blood platelets, which stop bleeding by clumping. The prevalence of thrombocytopenia among chemotherapy patients varies with the tumor type and chemotherapy used. It is particularly high among patients with colorectal (62%), cell lung (51%), and ovarian (46%) tumors.

Impact on Health

Thrombocytopenia can result in discontinuations/delays or reductions in chemotherapy doses, with potential implications for the success of patients' cancer treatment. It can also increase spontaneous bleeding and complicate surgical procedures. Platelet transfusions are used effectively but also introduce new risks for complications. Other recombinant proteins (TPO and rIL11) can be used but need to be discontinued after 14 days due to immunogenicity.

For information about our chemotherapy-induced thrombocytopenia therapy candidate, visit our Pipeline page.

References



Kuter, D. (2015). Managing thrombocytopenia associated with cancer chemotherapy. Oncology, 29(4).

Nielson C., Bylsma L., Fryzek J. et al. (2021). Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and META-ANALYSIS. The Oncologist, 26(9): e1609–e1618.

Ying Wu, Suresh Aravind, Gayatri Ranganathan, et al. (2009). Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: A descriptive study of a large outpatient oncology practice database, 2000– 2007[J]. Clinical Therapeutics, 31(2): 2416-2432.